Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 2, 2025

Study Completion Date

December 1, 2025

Conditions
Gastric and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)

arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)

Trial Locations (2)

03722

Severance Hospital, Seoul

Unknown

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER